

Diagnosis and Management of Severe Aplastic Anaemia in a Paediatric Patient: A Case Report

Sumaiyah Adzahar¹, Adibah Daud¹, Nurul Asyikin Nizam Akbar²

¹Department of Pathology, Faculty of Medicine, Universiti Sultan Zainal Abidin, Kuala Terengganu, Terengganu, Malaysia.

²Department of Haematology, School of Medical Sciences, Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia.

Corresponding author: srikandimaya11@gmail.com

Received: 25th June 2023

Accepted: 27th August 2023

Published: 20th October 2023

Abstract

Aplastic anaemia (AA) is a rare but severe haematologic condition that causes haematopoietic failure. This results in a decreased or absent number of haematopoietic precursor cells in the bone marrow. AA can occur at any age and affects both genders and all races equally. Here, we report a case of a 14-year-old boy who presented to the emergency department with multiple bruises over his body. Upon laboratory testing, he was discovered to have pancytopenia and a significant hypocellular marrow. The patient was treated with immunosuppressive therapy (IST) and planned for a bone marrow transplant after finding a suitable donor.

Keywords

Aplastic anaemia, pancytopenia, hypocellular marrow, immunosuppressive therapy (IST), bone marrow transplantation (BMT)

Introduction

Aplastic anaemia (AA) is a disorder of haematopoiesis characterized by pancytopenia and a hypocellular marrow without any apparent underlying neoplastic process. By definition, there is no presence of abnormal infiltration (such as leukemic or cancerous cells) or increase in reticulin in the bone marrow. AA exhibits a biphasic age distribution with a peak prevalence in those aged between 20 and 30 and over 60¹. It can be inherited or acquired. Several inherited AAs have been described, among which the most common are Fanconi anaemia, Dyskeratosis Congenita, Diamond Blackfan anaemia, and Schwachman-Diamond syndrome². Acquired AA can be caused by a variety of factors including radiation exposure, autoimmune disease, drugs (such as chloramphenicol), and chemicals (such as benzene).

Aplastic anaemia presents with signs and symptoms related to pancytopenia. Fatigue, pallor, and shortness of breath are associated with anaemia. Neutropenia correlates with an increased susceptibility to infections, and bleeding results from thrombocytopaenia can manifest as petechiae, ecchymoses, or

gastrointestinal bleeding. In cases of aplastic anaemia, there is no enlargement of the lymph nodes, liver, or spleen. A diagnosis other than aplastic anaemia should be considered if enlargement is detected³.

Severe aplastic anaemia (SAA) differs from its usual presentation of aplastic anaemia in terms of the severity and intensity of the condition. In SAA, this condition reaches a critical point where the bone marrow's ability to produce blood cells becomes severely impaired. The patient can present with more severe and life-threatening manifestations, including profound cytopenia that cause severe anaemia, a higher risk of serious infection, and uncontrolled bleeding. These will put them at a higher morbidity and mortality risk due to the severe depletion of blood cells. Here we present a case of severe aplastic anaemia in a 14-year-old boy.

Case Report

A 14-year-old boy was admitted to the hospital with a complaint of multiple bruises over his body, intermittent shortness of breath, and reduced effort tolerance for the past month. Upon physical examination, he was afebrile, with a blood pressure of 130/80 mmHg and a pulse rate of 98 beats per minute. Several bruises were found on his legs and thighs. His respiratory and cardiovascular system examinations were unremarkable. There was no palpable lymphadenopathy or hepatosplenomegaly and no physical abnormalities appointing towards inherited marrow failure syndrome IBMFSs.

Initial complete blood count revealed pancytopenia (Table 1). The reticulocyte count was 1%, normal lactate dehydrogenase (LDH), and negative Coomb test pointing toward hypo proliferative marrow rather than haemolysis. The liver function test, renal function test, and coagulation test were normal.

Peripheral blood smear showed pancytopenia with red blood cell anisopoikilocytosis, normal morphology of white blood cells (WBC), and platelets. The bone marrow aspiration showed markedly hypocellular fragments and trails, with no abnormal cells seen (see Figures 1 and 2). Bone marrow trephine biopsy revealed markedly hypocellular marrow with about 10% cells and 90% fats (Figure 3). There was no evidence of bone marrow infiltration by acute leukaemia, lymphoma, or non-hematopoietic cells. Flow cytometry study did not show presence of paroxysmal nocturnal haemoglobinuria (PNH) clone or acute leukaemia. Karyotyping also showed no abnormalities.

Further test results were negative for infection and connective tissue disease. He was diagnosed with severe aplastic anaemia according to Camitta criteria, 1976. The patient was started on triple immune suppression therapy: anti-thymocyte globulin (ATG), cyclosporine (CsA), and prednisone. He was planned for Hematopoietic Stem Cell Transplant (HSTC) later after finding a suitable donor.

Table 1: Blood results

Parameters	Value (Normal range)
Haemoglobin	5.2 (13.0 - 17.0 g/dL)
Total white blood cell count	3.9 (4 - 10 x 10 ⁹ /L)
Absolute neutrophil count	0.46 (2 - 7 x 10 ⁹ /L)
Platelet	2.0 (150-410 x 10 ⁹ /L)
Reticulocytes	1% (0.5 - 2.5%)
B12	149 (133-675 pg/mL)
Folate	16 (> 15 nmol/L)
Coomb test	Negative
Anti-HIV	Not reactive
Anti-HCV	Not reactive
HBsAg	Not reactive
Syphilis	Not reactive




Figure 1: BMA showed hypocellular marrow fragments.




Figure 2: BMA showed hypocellular cell trails.




Figure 3: Bone marrow trephine biopsy showed hypocellular marrow with 10% cellularity.

Discussion

We describe an interesting case of idiopathic severe aplastic anaemia in a 14-year-old boy. To diagnose AA there must be at least two of the following: haemoglobin concentration $<100\text{g/L}$, platelet count $<50 \times 10^9/\text{L}$, and neutrophil count $<1.5 \times 10^9/\text{L}^4$. The modified Camitta criteria are used to assess the severity in which severe AA is defined as marrow cellularity $<25\%$, plus at least 2 of: (i) neutrophils $<0.5 \times 10^9/\text{L}$, (ii) platelets $<20 \times 10^9/\text{L}$ and (iii) reticulocytes count $<20 \times 10^9/\text{L}^4$.

The first step in understanding the pathogenesis of AA is to divide it into inherited and acquired cases. Inherited marrow failure syndrome IBMFSs are disorders affecting important cellular functions such as DNA repair, telomere preservation, and ribosome biogenesis. While in acquired AA, the aetiologies include exposure to benzenes, radiation, infections (such as Epstein Barr Virus (EBV), Human Immunodeficiency Virus (HIV), parvovirus, and hepatitis), autoimmune disorders (such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Systemic Lupus Erythematosus (SLE)), and medications (such as alkylating agents, chloramphenicol, and anti-epileptics)^{2,5}. More commonly AA is idiopathic, and mounting evidence indicates that immune dysregulation is the underlying cause.

Many conditions are present in children with pancytopenia, some of which may also feature a hypocellular marrow and extensive investigations are mandatory to exclude them⁶. The comprehensive clinical course, family history, exposure to medications, toxins, infectious agents, physical abnormalities, and laboratory tests should be carefully evaluated. Meticulous investigations are required to confirm the diagnosis and: (i) exclude other causes of pancytopenia and hypocellular bone marrow, (ii) exclude inherited marrow failure syndrome IBMFSs (iii) screen for an underlying cause, and (iv) document co-existing abnormal cytogenetic, and PNH clones⁴. An appropriate evaluation of AA should include a complete blood count, reticulocytes count, peripheral smear, a bone marrow aspiration/biopsy, infective screening such as human immunodeficiency virus (HIV) / hepatitis serologies, vitamin B12/folate levels, flow cytometry to detect PNH or acute leukaemia and cytogenetic studies⁷.

A complete blood count, reticulocyte count, and peripheral blood smear is to confirm existing cytopenia and to rule out the signs of dysplasia. Trephine biopsy is crucial in the diagnosis of aplastic anaemia because of the frequent difficulty in obtaining an adequate aspirate with the result being a 'dry tap'. The bone marrow is usually hypocellular with a marked reduction of haemopoietic cells. A patchy pattern of erythropoiesis and megakaryopoiesis is typically absent in AA⁸. Myeloid cells are mainly replaced by fat but there is a variable inflammatory infiltrate composed of lymphocytes, plasma cells, macrophages, mast cells, and sometimes eosinophils. There is usually little if any increase in reticulin fibres. Infective screening is used to detect any infection that causes AA, and Vitamin B12 and folate level deficiency should be corrected before a final diagnosis of AA is confirmed. Flow cytometry is used to detect PNH clones that can occur in 50% of patients with AA. Majority of AA patients have normal cytogenetics, but some of these alterations are neither harmful nor suggestive of MDS (in the absence of dysplasia). These include, among others, trisomy 8, del13q, and loss of heterozygosity of the short arm of chromosome 6⁹.

In our case, the patient's medical history revealed no prior medication use and no known history of radiation or chemotherapy exposure, ruling out these common causes. Additionally, the absence of any viral infections or autoimmune disorders, normal serum vitamin B12/folate levels, no PNH clone or acute leukaemia or lymphoma detected in flow cytometry analysis and normal cytogenetic studies further complicated the diagnostic process. Despite the challenges posed by the idiopathic nature of his condition, the patient displayed remarkable stability and responded favourably to the tailored treatment plan.

Management of aplastic anaemia is directed at the underlying cause. Remove the offending agent(s), if possible. Initial management consists largely of supportive care with blood transfusions, platelet concentrates, and treatment and prevention of infection¹⁰. All blood products should be leucodepleted, to reduce the risk of alloimmunization, and irradiated, to prevent grafting of live donor lymphocyte.

Once a diagnosis is established, bone marrow transplantation (BMT) and full-dose immunosuppressive therapy (IST) using eltrombopag, anti-thymocytes (ATG), cyclosporin A and prednisone are the treatment of choices for AA patients in children and adults. Numerous studies have demonstrated that BMT is highly successful when an HLA-matched sibling is available (matched related donor, MRD), with 5-year survival rates of 90% and higher, making BMT the recommended first-line therapy in this setting¹¹.

Conclusion

This case report highlights the complexity and diagnostic difficulties associated with severe aplastic anaemia, serving as a valuable contribution to the existing literature and emphasizing the importance of early diagnosis and targeted management in paediatric patients to reduce the risks of morbidity and mortality.

Declaration

Author(s) declares that no conflict of interest.

References

1. Kasinathan G, Lee BS, Sathar J. Very severe aplastic anemia in an 80-year-old man. *Clin Case Rep.* 2021;9(3):1330-1333. doi:10.1002/ccr3.3757
2. Medinger M, Drexler B, Lengerke C, Passweg J. Pathogenesis of acquired aplastic anemia and the role of the bone marrow microenvironment. *Front Oncol.* 2018;8(DEC). doi:10.3389/fonc.2018.00587

3. Proskuriakova E, Jasaraj RB, San Hernandez AM, Sakhuja A, Khoury M, Khosla P. A Case of Severe Aplastic Anemia in a 35-Year-Old Male With a Good Response to Immunosuppressive Therapy. *Cureus*. Published online June 10, 2023. doi:10.7759/cureus.40210
4. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. *Br J Haematol*. 2016;172(2):187-207. doi:10.1111/bjh.13853
5. Sweeney R, Esmail F, Mirza KM, Nand S. Hypercellular bone marrow in aplastic anemia: A case report of two patients. *Clin Case Rep*. 2021;9(11). doi:10.1002/ccr3.4845
6. Scalzone M, Coccia P, Maurizi P, et al. Aplastic anaemia in childhood. Description of two cases and review of the literature. *Cent Eur J Med*. 2009;4(3):363-368. doi:10.2478/s11536-009-0024-7
7. Shimano KA, Narla A, Rose MJ, et al. Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium. *Am J Hematol*. 2021;96(11):1491-1504. doi:10.1002/ajh.26310
8. Iwafuchi H. The histopathology of bone marrow failure in children. *Journal of Clinical and Experimental Hematopathology*. 2018;58(2):68-86. doi:10.3960/jslrt.18018
9. DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. *Blood Adv*. 2021;5(12):2660-2671. doi:10.1182/bloodadvances.2021004345
10. Bacigalupo A. How I Treat How I treat acquired aplastic anemia. Published online 2017. doi:10.1182/blood-2016-08
11. Hartung HD, Olson TS, Bessler M. Acquired aplastic anemia in children. *Pediatr Clin North Am*. 2013;60(6):1311-1336. doi:10.1016/j.pcl.2013.08.011